Hsbc Holdings PLC Has $79,000 Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Hsbc Holdings PLC decreased its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) by 25.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 24,192 shares of the company’s stock after selling 8,175 shares during the period. Hsbc Holdings PLC’s holdings in Roivant Sciences were worth $79,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Citigroup Inc. increased its holdings in shares of Roivant Sciences by 1,803.6% during the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock valued at $28,000 after acquiring an additional 5,447 shares during the last quarter. Royal Bank of Canada boosted its stake in Roivant Sciences by 60,550.0% during the 1st quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock valued at $30,000 after purchasing an additional 6,055 shares during the period. Daiwa Securities Group Inc. bought a new stake in Roivant Sciences during the 3rd quarter valued at approximately $35,000. Pictet Asset Management SA bought a new stake in Roivant Sciences during the 2nd quarter valued at approximately $65,000. Finally, Goldman Sachs Group Inc. bought a new stake in Roivant Sciences during the 1st quarter valued at approximately $100,000. Institutional investors and hedge funds own 52.66% of the company’s stock.

Roivant Sciences Trading Down 0.5 %

ROIV stock opened at $7.65 on Monday. The business has a fifty day moving average price of $8.42 and a 200 day moving average price of $6.17. Roivant Sciences Ltd. has a fifty-two week low of $2.52 and a fifty-two week high of $10.00. The stock has a market capitalization of $5.80 billion, a price-to-earnings ratio of -4.30 and a beta of 1.26. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.74 and a quick ratio of 6.74.

Insider Activity at Roivant Sciences

In related news, Director Vivek Ramaswamy sold 4,000,000 shares of the firm’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $7.95, for a total transaction of $31,800,000.00. Following the completion of the sale, the director now directly owns 54,409,211 shares of the company’s stock, valued at approximately $432,553,227.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Eric Venker sold 24,037 shares of Roivant Sciences stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $8.02, for a total transaction of $192,776.74. Following the completion of the sale, the chief operating officer now directly owns 729,429 shares of the company’s stock, valued at $5,850,020.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Vivek Ramaswamy sold 4,000,000 shares of Roivant Sciences stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $7.95, for a total value of $31,800,000.00. Following the sale, the director now directly owns 54,409,211 shares of the company’s stock, valued at $432,553,227.45. The disclosure for this sale can be found here. Insiders sold 4,121,433 shares of company stock valued at $32,707,169 in the last three months. Corporate insiders own 13.00% of the company’s stock.

Analyst Ratings Changes

ROIV has been the subject of a number of research reports. SVB Leerink raised their price objective on Roivant Sciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Monday, December 19th. Citigroup raised their price objective on Roivant Sciences from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, January 5th. The Goldman Sachs Group raised their price objective on Roivant Sciences from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, January 19th. JPMorgan Chase & Co. raised their target price on Roivant Sciences from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, February 13th. Finally, HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $12.50.

Roivant Sciences Profile

(Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.